 Michael Shirts
Concepts (158)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Molecular Dynamics Simulation | 20 | 2024 | 217 | 7.080 |
Why?
| | Thermodynamics | 29 | 2023 | 408 | 3.910 |
Why?
| | Muramidase | 4 | 2020 | 77 | 1.660 |
Why?
| | Proteins | 14 | 2024 | 942 | 1.650 |
Why?
| | Solvents | 10 | 2020 | 108 | 1.240 |
Why?
| | Intrinsically Disordered Proteins | 2 | 2024 | 30 | 1.080 |
Why?
| | Protein Folding | 5 | 2024 | 266 | 0.960 |
Why?
| | Ligands | 11 | 2024 | 622 | 0.860 |
Why?
| | Models, Molecular | 9 | 2022 | 1492 | 0.820 |
Why?
| | Computer Simulation | 13 | 2022 | 943 | 0.820 |
Why?
| | Bayes Theorem | 2 | 2022 | 375 | 0.810 |
Why?
| | Terpenes | 1 | 2022 | 24 | 0.800 |
Why?
| | Water | 5 | 2016 | 448 | 0.800 |
Why?
| | Liquid Crystals | 1 | 2022 | 27 | 0.800 |
Why?
| | Nucleic Acids | 1 | 2022 | 60 | 0.760 |
Why?
| | Protein Binding | 15 | 2024 | 2121 | 0.720 |
Why?
| | Polymers | 1 | 2024 | 479 | 0.660 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2012 | 511 | 0.600 |
Why?
| | Monte Carlo Method | 5 | 2022 | 143 | 0.570 |
Why?
| | Amides | 2 | 2021 | 91 | 0.560 |
Why?
| | Models, Chemical | 8 | 2016 | 265 | 0.550 |
Why?
| | Bacteriophage T4 | 2 | 2013 | 15 | 0.540 |
Why?
| | Imidazoles | 3 | 2020 | 234 | 0.530 |
Why?
| | Drug Design | 5 | 2016 | 156 | 0.530 |
Why?
| | Selenium Compounds | 1 | 2016 | 21 | 0.510 |
Why?
| | Quantum Dots | 1 | 2016 | 36 | 0.500 |
Why?
| | Cadmium Compounds | 1 | 2016 | 31 | 0.500 |
Why?
| | Nanotubes, Carbon | 1 | 2016 | 42 | 0.500 |
Why?
| | Bridged-Ring Compounds | 2 | 2020 | 12 | 0.490 |
Why?
| | T-Lymphocytes | 1 | 2023 | 1928 | 0.480 |
Why?
| | Dextrans | 1 | 2015 | 82 | 0.460 |
Why?
| | Ethers, Cyclic | 1 | 2014 | 7 | 0.450 |
Why?
| | Resorcinols | 1 | 2014 | 5 | 0.450 |
Why?
| | Carboxylic Acids | 1 | 2014 | 32 | 0.440 |
Why?
| | Catalytic Domain | 3 | 2023 | 218 | 0.430 |
Why?
| | HIV Reverse Transcriptase | 1 | 2013 | 30 | 0.430 |
Why?
| | Molecular Conformation | 5 | 2024 | 144 | 0.420 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2013 | 83 | 0.420 |
Why?
| | Protein Structure, Secondary | 4 | 2023 | 341 | 0.410 |
Why?
| | Binding Sites | 6 | 2016 | 1252 | 0.400 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2012 | 64 | 0.380 |
Why?
| | Insulin | 1 | 2022 | 2326 | 0.370 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2012 | 171 | 0.360 |
Why?
| | Peptide Fragments | 3 | 2012 | 692 | 0.350 |
Why?
| | Amino Acids | 2 | 2021 | 485 | 0.320 |
Why?
| | Enzyme Inhibitors | 2 | 2023 | 827 | 0.320 |
Why?
| | Quantum Theory | 3 | 2020 | 82 | 0.310 |
Why?
| | RNA-Binding Proteins | 1 | 2012 | 388 | 0.310 |
Why?
| | Protein Conformation | 6 | 2015 | 859 | 0.310 |
Why?
| | Tacrolimus Binding Protein 1A | 2 | 2007 | 8 | 0.310 |
Why?
| | Software | 3 | 2018 | 608 | 0.270 |
Why?
| | Allosteric Site | 2 | 2023 | 19 | 0.270 |
Why?
| | Data Interpretation, Statistical | 1 | 2008 | 335 | 0.270 |
Why?
| | Tacrolimus | 1 | 2007 | 193 | 0.260 |
Why?
| | Peptides | 3 | 2023 | 925 | 0.250 |
Why?
| | Energy Transfer | 1 | 2005 | 51 | 0.230 |
Why?
| | Mammals | 2 | 2023 | 271 | 0.230 |
Why?
| | Entropy | 4 | 2023 | 39 | 0.230 |
Why?
| | Adsorption | 2 | 2015 | 139 | 0.220 |
Why?
| | Drug Discovery | 3 | 2016 | 131 | 0.220 |
Why?
| | Mutation | 2 | 2023 | 3717 | 0.220 |
Why?
| | Molecular Structure | 4 | 2021 | 482 | 0.220 |
Why?
| | Hydrogen Bonding | 2 | 2022 | 149 | 0.220 |
Why?
| | Bias | 1 | 2005 | 196 | 0.220 |
Why?
| | Biopolymers | 1 | 2024 | 33 | 0.220 |
Why?
| | Organelles | 1 | 2024 | 54 | 0.210 |
Why?
| | Biosensing Techniques | 1 | 2024 | 120 | 0.200 |
Why?
| | Protein Domains | 1 | 2024 | 253 | 0.200 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2023 | 168 | 0.200 |
Why?
| | Petroselinum | 1 | 2021 | 1 | 0.190 |
Why?
| | Models, Theoretical | 3 | 2020 | 547 | 0.190 |
Why?
| | Dimerization | 1 | 2022 | 192 | 0.190 |
Why?
| | Polysaccharides | 1 | 2022 | 86 | 0.190 |
Why?
| | Cellulase | 2 | 2012 | 31 | 0.190 |
Why?
| | Macrocyclic Compounds | 1 | 2020 | 9 | 0.170 |
Why?
| | Benchmarking | 1 | 2021 | 176 | 0.170 |
Why?
| | Uncertainty | 3 | 2016 | 116 | 0.160 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2020 | 361 | 0.160 |
Why?
| | Methane | 2 | 2013 | 48 | 0.160 |
Why?
| | Reproducibility of Results | 3 | 2018 | 3083 | 0.150 |
Why?
| | Algorithms | 4 | 2013 | 1622 | 0.140 |
Why?
| | Cyclohexanes | 1 | 2016 | 22 | 0.130 |
Why?
| | Electrons | 1 | 2016 | 79 | 0.120 |
Why?
| | Biophysics | 2 | 2006 | 68 | 0.120 |
Why?
| | Chromatography, Ion Exchange | 1 | 2015 | 52 | 0.120 |
Why?
| | Porosity | 1 | 2015 | 94 | 0.120 |
Why?
| | Static Electricity | 1 | 2015 | 116 | 0.120 |
Why?
| | Diffusion | 1 | 2015 | 117 | 0.120 |
Why?
| | Motion | 1 | 2015 | 98 | 0.110 |
Why?
| | Pharmaceutical Preparations | 1 | 2016 | 171 | 0.110 |
Why?
| | Glucosidases | 1 | 2013 | 3 | 0.110 |
Why?
| | Rilpivirine | 1 | 2013 | 7 | 0.110 |
Why?
| | Nevirapine | 1 | 2013 | 17 | 0.110 |
Why?
| | Oligosaccharides | 1 | 2013 | 57 | 0.110 |
Why?
| | Periodicity | 1 | 2013 | 57 | 0.100 |
Why?
| | Principal Component Analysis | 1 | 2013 | 189 | 0.100 |
Why?
| | Kinetics | 2 | 2015 | 1642 | 0.100 |
Why?
| | Biophysical Phenomena | 1 | 2013 | 64 | 0.100 |
Why?
| | Nitriles | 1 | 2013 | 172 | 0.100 |
Why?
| | Molecular Docking Simulation | 1 | 2012 | 109 | 0.100 |
Why?
| | Toluene | 1 | 2012 | 11 | 0.100 |
Why?
| | Deuterium Exchange Measurement | 1 | 2011 | 29 | 0.090 |
Why?
| | Complementarity Determining Regions | 1 | 2011 | 49 | 0.090 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2011 | 59 | 0.090 |
Why?
| | Trichoderma | 1 | 2011 | 27 | 0.090 |
Why?
| | Carbohydrates | 1 | 2011 | 64 | 0.090 |
Why?
| | Alanine | 1 | 2011 | 142 | 0.090 |
Why?
| | Fungal Proteins | 1 | 2011 | 130 | 0.090 |
Why?
| | Pyrimidines | 1 | 2013 | 459 | 0.080 |
Why?
| | Piperazines | 1 | 2012 | 342 | 0.080 |
Why?
| | Chemistry, Physical | 2 | 2006 | 37 | 0.080 |
Why?
| | Ethanol | 1 | 2013 | 589 | 0.070 |
Why?
| | Laboratories | 1 | 2008 | 110 | 0.070 |
Why?
| | Time Factors | 4 | 2013 | 6556 | 0.070 |
Why?
| | Computational Biology | 1 | 2011 | 599 | 0.060 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2011 | 759 | 0.060 |
Why?
| | Tacrolimus Binding Proteins | 1 | 2005 | 27 | 0.060 |
Why?
| | Benzoxazines | 1 | 2024 | 30 | 0.060 |
Why?
| | Humans | 8 | 2022 | 129650 | 0.060 |
Why?
| | Naphthalenes | 1 | 2024 | 57 | 0.060 |
Why?
| | Arabidopsis Proteins | 1 | 2024 | 68 | 0.050 |
Why?
| | Morpholines | 1 | 2024 | 122 | 0.050 |
Why?
| | Protein Engineering | 1 | 2024 | 105 | 0.050 |
Why?
| | Substrate Specificity | 2 | 2013 | 368 | 0.050 |
Why?
| | DNA | 1 | 2008 | 1400 | 0.050 |
Why?
| | Solubility | 2 | 2016 | 235 | 0.050 |
Why?
| | Circular Dichroism | 1 | 2021 | 148 | 0.040 |
Why?
| | Physical Phenomena | 1 | 2020 | 13 | 0.040 |
Why?
| | Temperature | 2 | 2011 | 636 | 0.040 |
Why?
| | Amino Acid Sequence | 3 | 2011 | 2058 | 0.040 |
Why?
| | Molecular Sequence Data | 3 | 2011 | 2832 | 0.030 |
Why?
| | Ecosystem | 1 | 2021 | 568 | 0.030 |
Why?
| | Small Molecule Libraries | 1 | 2016 | 86 | 0.030 |
Why?
| | Structure-Activity Relationship | 1 | 2016 | 548 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2015 | 264 | 0.030 |
Why?
| | Dextrins | 1 | 2012 | 3 | 0.020 |
Why?
| | Cellobiose | 1 | 2012 | 6 | 0.020 |
Why?
| | Glycoside Hydrolases | 1 | 2012 | 33 | 0.020 |
Why?
| | Cellulose | 1 | 2012 | 61 | 0.020 |
Why?
| | Chromatography, Gel | 1 | 2011 | 127 | 0.020 |
Why?
| | Animals | 2 | 2023 | 35361 | 0.020 |
Why?
| | Freezing | 1 | 2011 | 86 | 0.020 |
Why?
| | Protein Stability | 1 | 2011 | 162 | 0.020 |
Why?
| | Bevacizumab | 1 | 2011 | 129 | 0.020 |
Why?
| | Protein Multimerization | 1 | 2011 | 179 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2011 | 716 | 0.020 |
Why?
| | Probability | 1 | 2006 | 306 | 0.020 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2005 | 186 | 0.010 |
Why?
| | Cluster Analysis | 1 | 2006 | 482 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2011 | 1367 | 0.010 |
Why?
| | Viscosity | 1 | 2003 | 90 | 0.010 |
Why?
| | Models, Statistical | 1 | 2006 | 623 | 0.010 |
Why?
| | Neurofilament Proteins | 1 | 2002 | 43 | 0.010 |
Why?
| | Microfilament Proteins | 1 | 2003 | 129 | 0.010 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2002 | 257 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 2012 | 0.010 |
Why?
| | Nerve Tissue Proteins | 1 | 2003 | 570 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2003 | 743 | 0.010 |
Why?
|
|
Shirts's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|